
    
      This is an open, single-arm,multicenter 2 phase clinical study to evaluate efficacy and
      safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD19
      positive lymphoma. The study will be conducted using a phaseⅠ/Ⅱdesign the study will have the
      following sequential phases: part A (screening, leukapheresis, cell product preparation and
      cytoreductive chemotherapy) and part B (treatment and follow-up). The follow-up period for
      each participant is approximately 35 months after the final CAR-T infusion. The total
      duration of the study are expected to be approximately 3 years. A total of 24 patients may be
      enrolled over a period of 3 years.
    
  